Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalotimagene carmaleucel - AGC Biologics

Drug Profile

Nalotimagene carmaleucel - AGC Biologics

Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; Thymidine kinase cell therapy - AGC Biologics; TK; TK cell therapy - AGC Biologics; Zalmoxis

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MolMed
  • Developer AGC Biologics
  • Class Cell therapies; Gene therapies; Gene-directed enzyme-prodrug therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leukaemia

Most Recent Events

  • 01 Mar 2018 Launched for Leukaemia (Adjunctive treatment) in Italy (IV)
  • 26 Feb 2018 Launched for Leukaemia (Adjunctive treatment) in Germany (IV) before February 2018
  • 25 Jul 2017 Dompe acquires license and distribution rights to thymidine kinase cell therapy in European Economic Area (EEA), and option rights for Australia, Switzerland and Turkey for Haematological malignancies
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top